Kisspeptin-10
GnRH-Upstream Decapeptide
C-terminal decapeptide of kisspeptin — the primary endogenous driver of GnRH release. Available in 5 mg and 10 mg.
Growth Peptides
Category
From $53.99
Price
Research
Grade
Price
From $53.99
✓ 10% off via PeptidesMuscle
Suggested Protocol
Single-bolus research designs typically use 0.1–0.3nmol/kg intravenously or equivalent subcutaneous dosing for the LH-response reading. Short infusion protocols (60–120 minutes at 0.05–0.2nmol/kg/hr) generally fit within one 5mg vial per subject per session.
Kisspeptin-10 at the 5mg scale is built around a different research use case than the 10mg version. Single-session KISS1R challenge tests — the most common application in published human research — rarely consume more than a few hundred micrograms in total. A 5mg vial is sized for those discrete protocols: one reconstitution, one or two testing sessions, clean consumption inside the post-reconstitution stability window.
Protocol Sizing
Why 5mg Fits the Acute-Challenge Design
Most published kisspeptin human-research endpoints are single-session LH-response readings or short infusions spanning a few hours. A 5mg vial holds more than enough peptide for these protocols while avoiding the tail-end waste of a longer stability window.
Reconstitution Economics
One Vial, One Protocol, One Stability Window
At the dose footprint of an acute challenge test, 5mg yields multiple single-subject sessions without pushing against the 28-day reconstituted stability envelope. That is cleaner than splitting a 10mg vial across spaced-out sessions.
When 5mg Is Not Enough
Triggers to Size Up to 10mg
Multi-day pulsatile infusion arms, cohort studies with multiple subjects per reconstitution, or research designs asking questions about chronic KISS1R engagement rather than acute response all exceed 5mg quickly — at that point the 10mg vial is the correct operational choice.
Documented Effects
Sized for discrete stimulation-test protocols rather than chronic pulsatile infusion
Single reconstitution covers short research windows without end-of-cycle wastage
Same KISS1R-targeting peptide chemistry as the 10mg size
Matches the dose footprint of most published acute-challenge LH-response studies
Cleaner cost basis for single-investigator pilot arms
Appropriate scale for methods-development work before scaling to full cohort studies
Specifications
| Product | Kisspeptin-10 |
|---|---|
| Category | Growth Peptides |
| Format | Lyophilized powder |
| Price | From $53.99 |
Complementary Compounds
Research Protocol
Single-bolus research designs typically use 0.1–0.3nmol/kg intravenously or equivalent subcutaneous dosing for the LH-response reading. Short infusion protocols (60–120 minutes at 0.05–0.2nmol/kg/hr) generally fit within one 5mg vial per subject per session.
Kisspeptin-10 — FAQs
Related Growth Peptides Research
View All
Tesamorelin
N-terminally trans-3-hexenoyl-modified GHRH(1-44) with enhanced plasma stability. Research focus on visceral-adipose reduction. Available in 10 mg and 20 mg sizes.
GHRP-6 10mg
GHRP-6 10mg — the original His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 hexapeptide from the Bowers lab, distinguished by its strong orexigenic signal alongside GHS-R1a activation.
IGF-1 LR3 1mg
IGF-1 LR3 is a long-R3 analogue of native IGF-1 — an 83-residue recombinant protein with Arg3 substitution and a 13-residue N-terminal extension that extends plasma half-life from minutes to roughly twelve hours and dramatically weakens IGFBP binding.
